AKEBIA THERAPEUTICS INC (AKBA)

US00972D1054 - Common Stock

0.91  -0.03 (-3.19%)

After market: 0.945 +0.03 (+3.85%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AKEBIA THERAPEUTICS INC

NASDAQ:AKBA (6/21/2024, 7:00:00 PM)

After market: 0.945 +0.03 (+3.85%)

0.91

-0.03 (-3.19%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-23.53%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap190.74M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AKBA Daily chart

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 204 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing and commercializing therapeutics that serve as a foundation for future growth. The firm's portfolio includes Auryxia (ferric citrate), Vafseo (vadadustat), and HIF-PH inhibitors. Auryxia is a non-calcium, non-chewable, orally administered tablet, which controls the serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease, (DD-CKD), or the hyperphosphatemia Indication, and the treatment of iron deficiency anemia. Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, that is approved in Japan for the treatment of anemia due to chronic kidney disease (CKD), in adult patients. The firm utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Company Info

AKEBIA THERAPEUTICS INC

245 First Street

Cambridge MASSACHUSETTS 02142

P: 16178712098

CEO: John P. Butler

Employees: 204

Website: https://akebia.com/

AKBA News

News Image19 days ago - Akebia Therapeutics, Inc.Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

News Imagea month ago - Akebia Therapeutics, Inc.Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

News Imagea month ago - InvestorPlaceAKBA Stock Earnings: Akebia Therapeutics Misses EPS, Misses Revenue for Q1 2024

AKBA stock results show that Akebia Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Image2 months ago - Akebia Therapeutics, Inc.Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on...

News Image2 months ago - Akebia Therapeutics, Inc.Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

News Image3 months ago - Akebia Therapeutics, Inc.Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA Twits

Here you can normally see the latest stock twits on AKBA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example